The British national pharmaceuticals AstraZeneca vaccine to fight the novel coronavirus disease (Covid-19) has seen a robust immune response in older people, according to a report.
The Financial Times report, citing two unidentified people familiar with the finding, said the vaccine the company is making has produced protective antibodies and T cells in those in the oldest age groups.
AstraZeneca is producing the vaccine in collaboration with the University of Oxford.
Results from immunogenicity blood tests, which were carried out on a subset of older participants, echo data published in July showed that the vaccine was found to elicit ‘robust immune responses’ in healthy adults among the ages 18-55, further the report said.
AstraZeneca, along with Pfizer and Moderna, are among the pioneers in producing the Covid-19 vaccine around the world amid the increasing spread of the disease.
US regulators authorized AstraZeneca to restart its trials in the country for more than a month amid reports of a volunteer becoming ill. The US Food and Drug Administration authorized the resumption of the trial on Friday, according to statements issued by AstraZeneca and the University of Oxford.
Meanwhile, global Covid-19 cases are approaching the 43 million mark, according to information provided by the Johns Hopkins University tracker. The total number of cases currently stands at 4,2923,311 of which 1,152,978 people have succumbed to the infection.
.
